Paulo Lucio
Overview
Explore the profile of Paulo Lucio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergantim R, Geraldes C, Joao C, Lucio P, Neves M, Trigo F, et al.
EJHaem
. 2024 Dec;
5(6):1144-1153.
PMID: 39691257
Objectives: To characterize variations in real-world treatment patterns in multiple myeloma (MM) in Portugal over a 5-year period. Methods: A retrospective cohort multicenter study using secondary data of national hospital...
2.
Fernandes M, Gomes A, Oliveira M, Caldas J, Lucio P, Kim R, et al.
Haematologica
. 2024 Apr;
109(8):2671-2675.
PMID: 38654666
No abstract available.
3.
Joao C, Bergantim R, Santos J, Afonso C, Bernardo P, Coelho H, et al.
Acta Med Port
. 2023 Jul;
36(7-8):517-526.
PMID: 37429590
The treatment of multiple myeloma has profoundly changed with the introduction of several innovative therapies. The optimization of therapeutic sequencing through the combined use of the various drugs developed in...
4.
Constantino C, Leocadio S, Oliveira F, Silva M, Oliveira C, Castanheira J, et al.
J Digit Imaging
. 2023 Apr;
36(4):1864-1876.
PMID: 37059891
The objective is to assess the performance of seven semiautomatic and two fully automatic segmentation methods on [F]FDG PET/CT lymphoma images and evaluate their influence on tumor quantification. All lymphoma...
5.
Ferreira B, Carneiro E, Pestana C, Barahona F, Caetano J, Lopes R, et al.
Front Oncol
. 2022 Jul;
12:860849.
PMID: 35800053
Multiple myeloma (MM) is a hematological malignancy of clonal antibody-secreting plasma cells (PCs). MM diagnosis and risk stratification rely on bone marrow (BM) biopsy, an invasive procedure prone to sample...
6.
Mateos M, Dimopoulos M, Cavo M, Suzuki K, Knop S, Doyen C, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Aug;
21(11):785-798.
PMID: 34344638
Background: In the phase 3 ALCYONE study, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) versus bortezomib/melphalan/prednisone (VMP) significantly improved progression-free survival (PFS) and overall survival (OS) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM)...
7.
Knop S, Mateos M, Dimopoulos M, Suzuki K, Jakubowiak A, Doyen C, et al.
BMC Cancer
. 2021 Jun;
21(1):659.
PMID: 34078314
Background: In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple...
8.
Neves M, Trigo F, Rui B, Joao C, Lucio P, Mariana N, et al.
Pharmacoeconomics
. 2021 Jan;
39(5):579-587.
PMID: 33517511
Background: Multiple myeloma (MM) is the second most common hematological cancer worldwide and has significant morbidity and mortality and is increasing in incidence. While MM management costs are considerable, specific...
9.
Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate A, et al.
Leuk Lymphoma
. 2020 Apr;
61(8):1850-1859.
PMID: 32268815
In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or...
10.
Mateos M, Cavo M, Blade J, Dimopoulos M, Suzuki K, Jakubowiak A, et al.
Lancet
. 2019 Dec;
395(10218):132-141.
PMID: 31836199
Background: Standard-of-care treatment for patients with newly diagnosed multiple myeloma includes combination therapies for patients who are not eligible for autologous stem-cell transplantation. At the primary analysis for progression-free survival...